Sugi Predict

Sugi Predict / Compounds / SCHEMBL22404883

SCHEMBL22404883

SCHEMBL22404883

C=C1C(=O)N[C@@H](C)C(=O)N(C)[C@@H](C)C(=O)N[C@H]([C@@H](OC(=O)[C@@H](NC(=O)CC)[C@H](O)C(C)C)C(C)C)C(=O)N(C)[C@@H]([C@H](C)OC)C(=O)O[C@H](C(C)C)[C@H](NC(C)=O)C(=O)O[C@H](Cc2ccccc2)C(=O)N1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ GNA11 P29992 8/20 1.00
▸ GNAQ P50148 3/20 1.00
▸ FKBP1B P68106 1/20 0.32
▸ ELANE P08246 1/20 0.32
▸ ABCB1 P08183 1/20 0.32
▸ GHSR Q92847 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22133450 1.00 GNA11 (1.00) GNA11GNAQFKBP1BELANEABCB1
SCHEMBL22139627 1.00 GNA11 (1.00) GNA11GNAQFKBP1BELANEABCB1
SCHEMBL22404881 1.00 GNA11 (1.00) GNA11GNAQFKBP1BELANEABCB1
SCHEMBL26121610 1.00 GNA11 (1.00) GNA11GNAQFKBP1BELANEABCB1
SCHEMBL22139625 0.96 GNA11 (0.93) GNA11GNAQFKBP1BELANEABCB1
SCHEMBL22139591 0.95 GNA11 (0.90) GNA11GNAQFKBP1BELANEABCB1
SCHEMBL22133449 0.93 GNA11 (0.87) GNA11GNAQELANE
SCHEMBL22133467 0.93 GNA11 (0.87) GNA11GNAQELANE
SCHEMBL22116269 0.92 GNA11 (0.86) GNA11GNAQELANE
SCHEMBL22139629 0.92 GNA11 (0.86) GNA11GNAQELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230130103-A1 TARGETED PHARMACOLOGICAL THERAPEUTICS IN UVEAL MELANOMA WASHINGTON UNIVERSITY 2023-04-27 — — US disclosed
US-20230130103-A1 TARGETED PHARMACOLOGICAL THERAPEUTICS IN UVEAL MELANOMA WASHINGTON UNIVERSITY 2023-04-27 — — US disclosed
US-20200282015-A1 TARGETED PHARMACOLOGICAL THERAPEUTICS IN UVEAL MELANOMA WASHINGTON UNIVERSITY 2020-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230130103-A1 TARGETED PHARMACOLOGICAL THERAPEUTICS IN UVEAL MELANOMA MC1R, GNAQ, MITF GNA11 363/4885GNAQ 2/4885FKBP1B 4047/4885
US-20200282015-A1 TARGETED PHARMACOLOGICAL THERAPEUTICS IN UVEAL MELANOMA MC1R, MITF, PRKACA GNA11 944/4885GNAQ 4/4885FKBP1B 4021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.